PC–CARE Act

I 118TH CONGRESS 1ST SESSION H. R. 1315 To amend the Public Health Service Act to establish a Prostate Cancer Coordinating Committee, and for other purposes. IN THE HOUSE OF REPRESENTATIVES MARCH 1, 2023 Mr. MURPHY introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Public Health Service Act to establish a Pros- tate Cancer Coordinating Committee, and for other pur- poses. Be it enacted by the Senate and House of Representa- 1 tives of the United States of America in Congress assembled, 2 SECTION 1. SHORT TITLE. 3 This Act may be cited as the ‘‘Prostate Cancer Com- 4 munity Assistance, Research and Education Act of 2023’’ 5 or the ‘‘PC–CARE Act’’. 6 SEC. 2. FINDINGS. 7 Congress finds the following: 8 (1) Prostate cancer is the most commonly diag- 9 nosed non-skin cancer and the second leading cause 10 VerDate Sep 11 2014 01:15 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H1315.IH H1315 pbinns on DSKJLVW7X2PROD with $$_JOB 2 •HR 1315 IH of cancer-related deaths among men in the United 1 States. 2 (2) Over 3,100,000 men in the United States 3 live with a prostate cancer diagnosis and it is esti- 4 mated that in 2023, 288,300 men will be diagnosed 5 with, and more than 34,700 men will die of, prostate 6 cancer. 7 (3) Men with at least one close relative who has 8 been diagnosed with prostate cancer have twice the 9 risk of having prostate cancer compared to the gen- 10 eral population. 11 (4) At least 12 percent of men with metastatic 12 prostate cancer have inherited predispositions to the 13 disease and potentially actionable genomic alter- 14 ations have been identified in over 90 percent of 15 men with metastatic castration-resistant prostate 16 cancer. 17 (5) Advances in science to identify, test, and 18 treat these men at increased genetic risk of disease 19 are needed. 20 (6) African-American men suffer from a pros- 21 tate cancer incidence rate that is significantly higher 22 than that of White men and have more than double 23 the prostate cancer mortality rate than that of 24 White men. 25 VerDate Sep 11 2014 01:15 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H1315.IH H1315 pbinns on DSKJLVW7X2PROD with $$_JOB 3 •HR 1315 IH (7) Research has shown that veterans exposed 1 to herbicides, such as Agent Orange, are at higher 2 risk for and more likely to be diagnosed with aggres- 3 sive forms of prostate cancer. 4 (8) Screening by a digital rectal examination 5 and a prostate-specific antigen blood test can detect 6 the disease at the earlier, more treatable stages. 7 (9) Men diagnosed with early stage disease have 8 a nearly 100 percent 5-year survival rate but only 9 30 percent of men survive more than 5 years if diag- 10 nosed with prostate cancer after the cancer has me- 11 tastasized. 12 (10) Early-staged prostate cancer has no symp- 13 toms, raising the importance of early detection and 14 screening. 15 (11) The Department of Health and Human 16 Services, the Department of Defense, and the De- 17 partment of Veterans Affairs all have a role in pro- 18 viding care for and conducting research on prostate 19 cancer. 20 (12) Multiple institutes at the National Insti- 21 tutes of Health are engaged in prostate cancer care 22 and research, including the National Cancer Insti- 23 tute, National Institute of Biomedical Imaging and 24 Bioengineering, the National Institute on Minority 25 VerDate Sep 11 2014 01:15 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H1315.IH H1315 pbinns on DSKJLVW7X2PROD with $$_JOB 4 •HR 1315 IH Health and Health Disparities, and the Clinical Cen- 1 ter. 2 (13) Additional agencies and offices within the 3 Department of Health and Human Services conduct 4 activities related to prostate cancer, including the 5 Centers for Medicare and Medicaid Services, the 6 Centers for Disease Control and Prevention, the 7 Food and Drug Administration, the Health Re- 8 sources and Services Administration, the Office of 9 Minority Health, and the Agency for Healthcare Re- 10 search and Quality. 11 (14) The Department of Defense created the 12 Prostate Cancer Research Program in 1997 and has 13 funded more than $2,000,000,000 in prostate cancer 14 research since that time. 15 (15) Private foundations have provided substan- 16 tial funding to the prostate cancer research commu- 17 nity for almost three decades, including support for 18 over 200 cancer centers and universities. 19 (16) The Director of the National Institutes of 20 Health has partnered with private prostate cancer 21 research groups to study to study biological and 22 nonbiological factors associated with aggressive pros- 23 tate cancer in African-American men. 24 VerDate Sep 11 2014 01:15 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\H1315.IH H1315 pbinns on DSKJLVW7X2PROD with $$_JOB 5 •HR 1315 IH (17) The Secretary of Veterans Affairs has 1 partnered with private foundations to establish pre- 2 cision oncology program hubs for prostate cancer. 3 (18) The Director of the Centers for Disease 4 Control and Prevention has partnered with multiple 5 private stakeholder groups to increase awareness 6 and education around prostate cancer in the general 7 population and among high-risk groups. 8 (19) Increased coordination of governmental 9 and nongovernmental activities can reduce costs and 10 increase effectiveness of ongoing work. 11 (20) Joint planning and goal setting across the 12 Government and private sector can create a pathway 13 toward eliminating prostate cancer deaths and im- 14 proving care for millions of men. 15 SEC. 3. PROSTATE CANCER COORDINATING COMMITTEE. 16 Part A of title IV of the Public Health Service Act 17 (42 U.S.C. 281 et seq.) is amended by adding at the end 18 the following: 19 ‘‘SEC. 404F. PROSTATE CANCER COORDINATING COM- 20 MITTEE. 21 ‘‘(a) ESTABLISHMENT.—The Secretary shall estab- 22 lish a committee to be known as the Prostate Cancer Co- 23 ordinating Committee (referred to in this section as the 24 ‘Coordinating Committee’). 25 VerDate Sep 11 2014 01:15 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\H1315.IH H1315 pbinns on DSKJLVW7X2PROD with $$_JOB 6 •HR 1315 IH ‘‘(b) DUTIES.—The Coordinating Committee shall— 1 ‘‘(1) monitor, coordinate, and evaluate activities 2 with respect to prostate cancer research programs 3 carried out by Federal agencies; and 4 ‘‘(2) develop and implement the plan under sub- 5 section (g). 6 ‘‘(c) COMPOSITION.— 7 ‘‘(1) IN GENERAL.—The Coordinating Com- 8 mittee shall be composed of not more than 24 mem- 9 bers, to be appointed by the Secretary, of whom— 10 ‘‘(A) one-half shall represent Federal agen- 11 cies that carry out research or treatment activi- 12 ties with respect to prostate cancer, including— 13 ‘‘(i) the Director of the National In- 14 stitutes of Health (or designee); 15 ‘‘(ii) the directors of the appropriate 16 agencies of the National Institutes of 17 Health (or designees), including the Na- 18 tional Cancer Institute; 19 ‘‘(iii) the Director of the Centers for 20 Disease Control and Prevention (or des- 21 ignee); 22 ‘‘(iv) the Administrator of the Health 23 Resources and Services Administration (or 24 designee); 25 VerDate Sep 11 2014 01:15 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\H1315.IH H1315 pbinns on DSKJLVW7X2PROD with $$_JOB 7 •HR 1315 IH ‘‘(v) the Administrator of the Centers 1 for Medicare & Medicaid Services (or des- 2 ignee); 3 ‘‘(vi) the Commissioner of Food and 4 Drugs (or designee); 5 ‘‘(vii) the Secretary of Defense (or 6 designee); and 7 ‘‘(viii) the Secretary of Veterans Af- 8 fairs (or designee); and 9 ‘‘(B) one-half shall be individuals who have 10 experience with prostate cancer, including— 11 ‘‘(i) not less than 3 individuals who 12 are living with prostate cancer (or a care- 13 giver of such individual); 14 ‘‘(ii) not less than 3 researchers; 15 ‘‘(iii) not less than 3 clinicians; 16 ‘‘(iv) not less than 3 representatives 17 from patient groups; and 18 ‘‘(v) not less than 3 representatives 19 from professional medical societies. 20 ‘‘(2) PHYSICIAN REQUIREMENT.—Of the mem- 21 bers appointed under paragraph (1), not less than 22 one-half shall be physicians. 23 ‘‘(d) TERM; VACANCIES.— 24 VerDate Sep 11 2014 01:15 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6201 E:\BILLS\H1315.IH H1315 pbinns on DSKJLVW7X2PROD with $$_JOB 8 •HR 1315 IH ‘‘(1) IN GENERAL.—A member shall be ap- 1 pointed for a term of 3 years. 2 ‘‘(2) VACANCIES.—A vacancy on the Coordi- 3 nating Committee shall be filled in the same manner 4 as the original appointment was made. 5 ‘‘(e) REAPPOINTMENT.—The Secretary may re- 6 appoint a member of the Coordinating Committee to an 7 unlimited number of terms. 8 ‘‘(f) CHAIR.—The Secretary shall appoint the chair 9 of the Coordinating Committee. 10 ‘‘(g) PLAN.—Not later than 1 year after the date of 11 the enactment of this section, the Coordinating Committee 12 shall develop and implement a plan (and update such plan 13 every 3 years thereafter), in consultation with a broad 14 range of scientists, patients, clinicians, and advocacy 15 groups, on prostate cancer research programs and activi- 16 ties carried out by Federal agencies. Such plan shall in- 17 clude the following: 18 ‘‘(1) The identification of existing prostate can- 19 cer programs and activities of the— 20 ‘‘(A) the Department of Health and 21 Human Services, including the National Insti- 22 tutes of Health; 23 ‘‘(B) the Department of Defense; and 24 ‘‘(C) the Department of Veterans Affairs. 25 VerDate Sep 11 2014 01:15 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00008 Fmt 6652 Sfmt 6201 E:\BILLS\H1315.IH H1315 pbinns on DSKJLVW7X2PROD with $$_JOB 9 •HR 1315 IH ‘‘(2) An evaluation on research with respect to 1 the underlying causes, prevalence, treatment, and 2 mortality of prostate cancer, including any disparity 3 among African-American and other high-risk men 4 (defined as men who have a family history of pros- 5 tate cancer, a genetic predisposition for prostate 6 cancer, or developed cancer due to exposure to cer- 7 tain chemical and radiological agents). 8 ‘‘(3) With respect to prostate cancer— 9 ‘‘(A) an evaluation on the effectiveness of 10 current screening and diagnostic techniques; 11 and 12 ‘‘(B) recommendations for improving such 13 techniques. 14 ‘‘(4) An evaluation on the effectiveness of treat- 15 ments for prostate cancer and the development of 16 recommendations for new treatments, including new 17 biological agents. 18 ‘‘(5) With respect to prostate cancer, an evalua- 19 tion on the effectiveness of clinical practice guide- 20 lines and the development of recommendations to 21 improve such guidelines. 22 ‘‘(6) The development of recommendations to 23 improve clinical pathways in private and govern- 24 ment-operated medical systems, including screening 25 VerDate Sep 11 2014 01:15 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00009 Fmt 6652 Sfmt 6201 E:\BILLS\H1315.IH H1315 pbinns on DSKJLVW7X2PROD with $$_JOB 10 •HR 1315 IH and diagnosis and information on informed and 1 shared decision making. 2 ‘‘(7) The development of recommendations for 3 research investigation methods for improving the 4 quality of life of individuals who have survived with 5 prostate cancer. 6 ‘‘(8) With respect to prostate cancer, an evalua- 7 tion on the effectiveness of information and edu- 8 cation programs for health care professionals and 9 the public. 10 ‘‘(9) With respect to screening and clinical trial 11 enrollment for prostate cancer, recommendations to 12 improve outreach and education, including best prac- 13 tices for outreach to African-American men and 14 other high-risk men. 15 ‘‘(h) MEETINGS.—The Coordinating Committee shall 16 meet at the request of the Secretary not less 3 times each 17 year. 18 ‘‘(i) FACA.—Except as provided in this section, the 19 Federal Advisory Committee Act (5 U.S.C. App.) shall not 20 apply to the Coordinating Committee. 21 ‘‘(j) REPORT.— 22 ‘‘(1) INITIAL REPORT.—Not later than 1 year 23 after the date of the enactment of this section, the 24 Coordinating Committee shall submit recommenda- 25 VerDate Sep 11 2014 01:15 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00010 Fmt 6652 Sfmt 6201 E:\BILLS\H1315.IH H1315 pbinns on DSKJLVW7X2PROD with $$_JOB 11 •HR 1315 IH tions using the plan under subsection (g) to the fol- 1 lowing: 2 ‘‘(A) The Secretary of the Department of 3 Health and Human Services. 4 ‘‘(B) The Secretary of Defense. 5 ‘‘(C) The Secretary of Veterans Affairs. 6 ‘‘(D) The Committees on Energy and 7 Commerce and Appropriations of the House of 8 Representatives. 9 ‘‘(E) The Committees on Health, Edu- 10 cation, Labor, and Pensions and Appropriations 11 of the Senate. 12 ‘‘(2) UPDATED REPORTS.—Not later than 3 13 years after the date of the enactment of this section, 14 and every 3 years thereafter, the Coordinating Com- 15 mittee shall submit to the secretaries and commit- 16 tees listed in paragraph (1)— 17 ‘‘(A) updated recommendations using the 18 plan under subsection (g); and 19 ‘‘(B) a summary of progress made with re- 20 spect to recommendations submitted pursuant 21 to this section. 22 ‘‘(k) AUTHORIZATION OF APPROPRIATIONS.—There 23 are authorized to be appropriated to carry out this section 24 VerDate Sep 11 2014 01:15 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00011 Fmt 6652 Sfmt 6201 E:\BILLS\H1315.IH H1315 pbinns on DSKJLVW7X2PROD with $$_JOB 12 •HR 1315 IH such sums as may be necessary for each of fiscal years 1 2024 through 2030.’’. 2 Æ VerDate Sep 11 2014 01:15 Apr 18, 2023 Jkt 039200 PO 00000 Frm 00012 Fmt 6652 Sfmt 6301 E:\BILLS\H1315.IH H1315 pbinns on DSKJLVW7X2PROD with $$_JOB